Reportlinker Adds Brazil In Vitro Diagnostics Market Outlook to 2016
NEW YORK, Aug. 10 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Brazil In Vitro Diagnostics Market Outlook to 2016
http://www.reportlinker.com/p0254509/Brazil-In-Vitro-Diagnostics-Market-Outlook-to-2016.html
Netherlands In Vitro Diagnostics Market Outlook to 2016
Summary
GlobalData's new report, "Netherlands In Vitro Diagnostics Market Outlook to 2016" provides key market data on the Netherlands In Vitro Diagnostics (IVD) market. The report provides value (USD million), volume (units) and average price (USD) data for each segment and sub-segment within seven market categories – clinical chemistry, genetic testing, histology and cytology, immuno chemistry, infectious immunology, microbiology culture, and haematology. The report also provides company shares and distribution shares data for each of the aforementioned market categories. The report is supplemented with global corporate-level profiles of the key market participants with information on company financials and pipeline products, wherever available.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.
Scope
- Market size and company share data for In Vitro Diagnostics (IVD) market categories – clinical chemistry, genetic testing, histology and cytology, immuno chemistry, infectious immunology, microbiology culture, and haematology.
- Annualized market revenues (USD million), volume (units) and average price (USD) data for each of the segments and sub-segments within seven market categories. Data from 2002 to 2009, forecast forward for 7 years to 2016.
- 2009 company shares and distribution shares data for each of the seven market categories.
- Global corporate-level profiles of key companies operating within the Netherlands In Vitro Diagnostics (IVD) market.
- Key players covered include Roche, Siemens Healthcare, Abbott, Beckman Coulter, Biomerieux, Ortho-Clinical Diagnostics, and Becton, Dickinson.
Reasons to buy
- Develop business strategies by identifying the key market categories and segments poised for strong growth.
- Develop market-entry and market expansion strategies.
- Design competition strategies by identifying who-stands-where in the Netherlands In Vitro Diagnostics (IVD) competitive landscape.
- Develop capital investment strategies by identifying the key market segments expected to register strong growth in the near future.
- What are the key distribution channels and what's the most preferred mode of product distribution – Identify, understand and capitalize.
Table of Contents
1 Table of Contents 2
1.1 List of Tables 9
1.2 List of Figures 12
2 Introduction 15
2.1 What is This Report About? 15
3 In Vitro Diagnostics In Netherlands 16
3.1 3.1 In Vitro Diagnostics, Market Segmentation 16
3.2 In Vitro Diagnostics, Netherlands, Overall Revenue ($m), 2002-2016 17
3.3 In Vitro Diagnostics Market, Netherlands, Revenue Mix ($m), 2009 19
3.4 In Vitro Diagnostics Market, Netherlands, Category Contribution (%), 2009 20
3.5 In Vitro Diagnostics, Netherlands, Company Share (2008-2009) 26
4 Clinical Chemistry In Netherlands 28
4.1 Clinical Chemistry, Market Segmentation 28
4.2 Clinical Chemistry Market, Netherlands, Revenue Mix ($m), 2009 29
4.3 Clinical Chemistry Market, Netherlands, Category Contribution (%), 2009 30
4.4 Clinical Chemistry Overall Revenue (2002-2016) 31
4.4.1 Clinical Chemistry Analyzers Revenue (2002-2016) 35
4.4.2 Urine Analysis Revenue (2002-2016) 39
4.5 Clinical Chemistry Distribution Share (2008-2009) 43
4.6 Clinical Chemistry, Netherlands, Company Share (2008-2009) 44
5 Genetic Testing In Netherlands 46
5.1 Genetic Testing, Market Segmentation 46
5.2 Genetic Testing Market, Netherlands, Revenue Mix ($m), 2009 47
5.3 Genetic Testing Market, Netherlands, Category Contribution (%), 2009 48
5.4 Genetic Testing Overall Revenue (2002-2016) 49
5.5 Genetic Testing Distribution Share (2008-2009) 53
5.6 Genetic Testing, Netherlands, Company Share (2008-2009) 54
6 Haematology In Netherlands 55
6.1 Haematology, Market Segmentation 55
6.2 Heamatology Market, Netherlands, Revenue Mix ($m), 2009 56
6.3 Haematology Market, Netherlands, Category Contribution (%), 2009 57
6.4 Haematology Overall Revenue (2002-2016) 58
6.4.1 Haematology Reagnets Revenue (2002-2016) 62
6.4.2 Immunohaematology Revenue (2002-2016) 66
6.4.3 Haemostasis Revenue (2002-2016) 70
6.4.4 Haematology Rapid Tests Revenue (2002-2016) 74
6.4.5 Haematology Cell Counters Revenue (2002-2016) 78
6.5 Haematology Distribution Share (2008-2009) 82
6.6 Haematology, Netherlands, Company Share (2008-2009) 83
7 Histology And Cytology In Netherlands 85
7.1 Histology and Cytology, Market Segmentation 85
7.2 Histology and Cytology Market, Netherlands, Revenue Mix ($m), 2009 86
7.3 Histology and Cytology Market, Netherlands, Category Contribution (%), 2009 87
7.4 Histology and Cytology Overall Revenue (2002-2016) 88
7.4.1 Histology Revenue (2002-2016) 92
7.5 Histology And Cytology Distribution Share (2008-2009) 96
7.6 Histology And Cytology, Netherlands, Company Share (2008-2009) 97
8 Immuno Chemistry In Netherlands 99
8.1 Immuno Chemistry, Market Segmentation 99
8.2 Immuno Chemistry Market, Netherlands, Revenue Mix ($m), 2009 100
8.3 Immuno Chemistry Market, Netherlands, Category Contribution (%), 2009 101
8.4 Immuno Chemistry Overall Revenue (2002-2016) 102
8.4.1 Disease Specific Immunochemistry Revenue (2002-2016) 106
8.4.2 Drug Related Testing Revenue (2002-2016) 110
8.4.3 Endocrinology Tests Revenue (2002-2016) 114
8.4.4 Immunochemistry Analyzers Revenue (2002-2016) 118
8.5 Immuno Chemistry Distribution Share (2008-2009) 122
8.6 Immuno Chemistry, Netherlands, Company Share (2008-2009) 123
9 Infectious Immunology In Netherlands 125
9.1 Infectious Immunology, Market Segmentation 125
9.2 Infectious Immunology Market, Netherlands, Revenue Mix ($m), 2009 126
9.3 Infectious Immunology Market, Netherlands, Category Contribution (%), 2009 127
9.4 Infectious Immunology Overall Revenue (2002-2016) 128
9.5 Infectious Immunology Distribution Share (2008-2009) 132
9.6 Infectious Immunology, Netherlands, Company Share (2008-2009) 133
10 Microbiology Culture In Netherlands 135
10.1 Microbiology Culture, Market Segmentation 135
10.2 Microbiology Culture Market, Netherlands, Revenue Mix ($m), 2009 136
10.3 Microbiology Culture Market, Netherlands, Category Contribution (%), 2009 137
10.4 Microbiology Culture Overall Revenue (2002-2016) 138
10.4.1 Microbiology Analyzers Revenue (2002-2016) 142
10.5 Microbiology Culture Distribution Share (2008-2009) 146
10.6 Microbiology Culture, Netherlands, Company Share (2008-2009) 147
11 Overview of Key Companies in Netherlands In Vitro Diagnostics Market 149
11.1 F. Hoffmann-La Roche Ltd. 149
11.1.1 Company Overview 149
11.1.2 Share in the Netherlands In Vitro Diagnostics Market 149
11.2 Siemens Healthcare 151
11.2.1 Company Overview 151
11.2.2 Share in the Netherlands In Vitro Diagnostics Market 151
11.3 Abbott Laboratories 152
11.3.1 Company Overview 152
11.3.2 Share in the Netherlands In Vitro Diagnostics Market 152
11.4 bioMerieux S.A. 153
11.4.1 Company Overview 153
11.4.2 Share in the Netherlands In Vitro Diagnostics Market 153
11.5 Beckman Coulter, Inc. 154
11.5.1 Company Overview 154
11.5.2 Share in the Netherlands In Vitro Diagnostics Market 154
11.6 Ortho-Clinical Diagnostics Inc. 155
11.6.1 Company Overview 155
11.6.2 Share in the Netherlands In Vitro Diagnostics Market 155
11.7 Inverness Medical Innovations, Inc. 156
11.7.1 Company Overview 156
11.8 Becton, Dickinson and Company 156
11.8.1 Company Overview 156
11.9 Bio-Rad Laboratories, Inc. 157
11.9.1 Company Overview 157
11.10 Hologic, Inc. 157
11.10.1 Company Overview 157
11.11 OLYMPUS CORPORATION 158
11.11.1 Company Overview 158
11.12 Mindray Medical International Limited 158
11.12.1 Company Overview 158
11.13 Sysmex Corporation 158
11.13.1 Company Overview 158
11.14 Ventana Medical Systems, Inc. 159
11.14.1 Company Overview 159
11.15 DiaSorin S.p.A 159
11.15.1 Company Overview 159
11.16 Qiagen N.V. 159
11.16.1 Company Overview 159
11.17 Gen-Probe Incorporated 160
11.17.1 Company Overview 160
11.18 Phadia AB 160
11.18.1 Company Overview 160
11.19 Vital Scientific B.V. 160
11.19.1 Company Overview 160
11.20 Nucletron B.V. 161
11.20.1 Company Overview 161
11.21 Kreatech Holding B.V. 161
11.21.1 Company Overview 161
11.22 Nordic Immunological Laboratories 161
11.22.1 Company Overview 161
11.23 Agendia BV 162
11.23.1 Company Overview 162
11.24 Adamas Instrumenten bv 162
11.24.1 Company Overview 162
11.25 Be Kerkhof 162
11.25.1 Company Overview 162
12 In Vitro Diagnostics Market Pipeline Products 163
12.1 Clinical Chemistry Market Pipeline Products 163
12.2 Immuno Chemistry Market Pipeline Products 165
12.3 Haematology Market Pipeline Products 167
12.4 Infectious Immunology Market Pipeline Products 168
12.5 Microbiology Culture Market Pipeline Products 170
12.6 Histology and Cytology Market Pipeline Products 171
12.7 Genetic Testing Market Pipeline Products 172
13 Financial Deals Landscape 174
13.1 Partnerships 174
13.1.1 QIAGEN Enters Into Distribution Agreement With Celera 174
13.1.2 Sequenom Enters Into Licensing Agreement With Optherion 175
13.1.3 QIAGEN Enters Into Licensing Agreement With Johns Hopkins University 176
13.1.4 DiaGenic Enters Into Distribution Agreement With Ferrer inCode 177
13.1.5 OraSure Technologies Enters Into An Agreement With Roche Diagnostics 178
13.1.6 Royal Philips Electronics Enters Into An Agreement With bioMerieux 179
13.1.7 Technogenetics Signs Distribution Agreement With A. Menarini Diagnostics 180
13.1.8 Inverness Medical Innovations Enters Into Distribution Agreement With Epocal 182
13.1.9 Radient Pharmaceuticals Enters Into An Agreement With GenWay Biotech 183
13.1.10 Amsterdam Molecular Therapeutics Enters Into An Agreement With Progenika Biopharma 184
13.1.11 QIAGEN Enters Into An Agreement With Roche And Idaho Technology 185
13.1.12 Leica Microsystems Signs An Agreement With A. Menarini Diagnostics 186
14 Recent Developments 187
14.1 Strategy and Business Planning 187
14.1.1 Jun 17, 2010: QIAGEN Expands Partnership with Genome Diagnostics For Development Of New Tests For Applications In Prevention And Personalized Healthcare 187
14.1.2 Dec 08, 2009: Genetix Expands Sales, Support And Service Organization In France And Benelux 188
14.2 Government and Public Interest 188
14.2.1 Jun 28, 2010: Cheap, Simple, Noninvasive Blood Test May Replace Invasive Diagnostic Techniques In Early Pregnancy: Dutch Researchers 188
14.2.2 Mar 16, 2010: Home-Testing Kits Could Help To Detect HPV In Women Who Do Not Attend Cervical Screening 189
14.3 Product News 190
14.3.1 Jan 25, 2010: Qiagen Introduces QIAsymphony AS 190
14.3.2 Oct 29, 2009: Amsredam Molecular Therapeutics Enters An Agreement With Progenika To Develop LPL Chip 190
14.3.3 Sep 10, 2009: QIAGEN Introduces Artus Influenza/H1 RG/LC RT-PCR Kit 191
15 Appendix 193
15.1 Definitions of Markets Covered in the Report 194
15.1.1 In Vitro Diagnostics 194
15.2 Research Methodology 202
15.3 Secondary Research 203
15.4 Primary Research 203
15.5 Models 204
15.6 Forecasts 204
15.7 Expert Panels 204
15.8 GlobalData Consulting 204
15.9 Currency Conversion 205
15.10 Contact Us 205
15.11 Disclaimer 205
List of Tables
1.1 List of Tables
Table 1: In Vitro Diagnostics, Netherlands, Overall Revenue ($m), 2002-2016 18
Table 2: In Vitro Diagnostics Market, Netherlands, Category Contribution (%), 2009 20
Table 3: In Vitro Diagnostics, Netherlands, Cross-Category Analysis, 2002-2016 21
Table 4: In Vitro Diagnostics, Netherlands, Overall Revenue ($m), Historic, 2002-2009 23
Table 5: In Vitro Diagnostics, Netherlands, Overall Revenue ($m), Forecast, 2009-2016 25
Table 6: In Vitro Diagnostics, Netherlands, Company Share by Revenue ($m), 2008-2009 27
Table 7: Clinical Chemistry, Netherlands, Category Contribution (%), 2009 30
Table 8: Clinical Chemistry, Netherlands, Revenue ($m) by Segment, Historic, 2002-2009 32
Table 9: Clinical Chemistry, Netherlands, Revenue ($m) by Segment, Forecast, 2009-2016 34
Table 10: Clinical Chemistry Analyzers, Netherlands, Revenue ($m) by Sub-Segment, Historic, 2002-2009 36
Table 11: Clinical Chemistry Analyzers, Netherlands, Revenue ($m) by Sub-Segment, Forecast, 2009-2016 38
Table 12: Urine Analysis, Netherlands, Revenue ($m) by Sub-Segment, Historic, 2002-2009 40
Table 13: Urine Analysis, Netherlands, Revenue ($m) by Sub-Segment, Forecast, 2009-2016 42
Table 14: Clinical Chemistry, Netherlands, Distribution Share by Revenue ($m), 2008-2009 43
Table 15: Clinical Chemistry, Netherlands, Company Share by Revenue ($m), 2008-2009 45
Table 16: Genetic Testing Market, Netherlands, Category Contribution (%), 2009 48
Table 17: Genetic Testing, Netherlands, Revenue ($m) by Segment, Historic, 2002-2009 50
Table 18: Genetic Testing, Netherlands, Revenue ($m) by Segment, Forecast, 2009-2016 52
Table 19: Genetic Testing, Netherlands, Distribution Share by Revenue ($m), 2008-2009 53
Table 20: Genetic Testing, Netherlands, Company Share by Revenue ($m), 2008-2009 54
Table 21: Haematology Market, Netherlands, Category Contribution (%), 2009 57
Table 22: Haematology, Netherlands, Revenue ($m) by Segment, Historic, 2002-2009 59
Table 23: Haematology, Netherlands, Revenue ($m) by Segment, Forecast, 2009-2016 61
Table 24: Haematology Reagents, Netherlands, Revenue ($m) by Sub-Segment, Historic, 2002-2009 63
Table 25: Haematology Reagents, Netherlands, Revenue ($m) by Sub-Segment, Forecast, 2009-2016 65
Table 26: Immunohaematology, Netherlands, Revenue ($m) by Sub-Segment, Historic, 2002-2009 67
Table 27: Immunohaematology, Netherlands, Revenue ($m) by Sub-Segment, Forecast, 2009-2016 69
Table 28: Haemostasis, Netherlands, Revenue ($m) by Sub-Segment, Historic, 2002-2009 71
Table 29: Haemostasis, Netherlands, Revenue ($m) by Sub-Segment, Forecast, 2009-2016 73
Table 30: Haematology Rapid Tests, Netherlands, Revenue ($m) by Sub-Segment, Historic, 2002-2009 75
Table 31: Haematology Rapid Tests, Netherlands, Revenue ($m) by Sub-Segment, Forecast, 2009-2016 77
Table 32: Haematology Cell Counters, Netherlands, Revenue ($m) by Sub-Segment, Historic, 2002-2009 79
Table 33: Haematology Cell Counters, Netherlands, Revenue ($m) by Sub-Segment, Forecast, 2009-2016 81
Table 34: Haematology, Netherlands, Distribution Share by Revenue ($m), 2008-2009 82
Table 35: Haematology, Netherlands, Company Share by Revenue ($m), 2008-2009 84
Table 36: Histology and Cytology Market, Netherlands, Category Contribution (%), 2009 87
Table 37: Histology And Cytology, Netherlands, Revenue ($m) by Segment, Historic, 2002-2009 89
Table 38: Histology And Cytology, Netherlands, Revenue ($m) by Segment, Forecast, 2009-2016 91
Table 39: Histology, Netherlands, Revenue ($m) by Sub-Segment, Historic, 2002-2009 93
Table 40: Histology, Netherlands, Revenue ($m) by Sub-Segment, Forecast, 2009-2016 95
Table 41: Histology And Cytology, Netherlands, Distribution Share by Revenue ($m), 2008-2009 96
Table 42: Histology And Cytology, Netherlands, Company Share by Revenue ($m), 2008-2009 98
Table 43: Immuno Chemistry Market, Netherlands, Category Contribution (%), 2009 101
Table 44: Immuno Chemistry, Netherlands, Revenue ($m) by Segment, Historic, 2002-2009 103
Table 45: Immuno Chemistry, Netherlands, Revenue ($m) by Segment, Forecast, 2009-2016 105
Table 46: Disease Specific Immunochemistry, Netherlands, Revenue ($m) by Sub-Segment, Historic, 2002-2009 107
Table 47: Disease Specific Immunochemistry, Netherlands, Revenue ($m) by Sub-Segment, Forecast, 2009-2016 109
Table 48: Drug Related Testing, Netherlands, Revenue ($m) by Sub-Segment, Historic, 2002-2009 111
Table 49: Drug Related Testing, Netherlands, Revenue ($m) by Sub-Segment, Forecast, 2009-2016 113
Table 50: Endocrinology Tests, Netherlands, Revenue ($m) by Sub-Segment, Historic, 2002-2009 115
Table 51: Endocrinology Tests, Netherlands, Revenue ($m) by Sub-Segment, Forecast, 2009-2016 117
Table 52: Immunochemistry Analyzers, Netherlands, Revenue ($m) by Sub-Segment, Historic, 2002-2009 119
Table 53: Immunochemistry Analyzers, Netherlands, Revenue ($m) by Sub-Segment, Forecast, 2009-2016 121
Table 54: Immuno Chemistry, Netherlands, Distribution Share by Revenue ($m), 2008-2009 122
Table 55: Immuno Chemistry, Netherlands, Company Share by Revenue ($m), 2008-2009 124
Table 56: Infectious Immunology Market, Netherlands, Category Contribution (%), 2009 127
Table 57: Infectious Immunology, Netherlands, Revenue ($m) by Segment, Historic, 2002-2009 129
Table 58: Infectious Immunology, Netherlands, Revenue ($m) by Segment, Forecast, 2009-2016 131
Table 59: Infectious Immunology, Netherlands, Distribution Share by Revenue ($m), 2008-2009 132
Table 60: Infectious Immunology, Netherlands, Company Share by Revenue ($m), 2008-2009 134
Table 61: Microbiology Culture Market, Netherlands, Category Contribution (%), 2009 137
Table 62: Microbiology Culture, Netherlands, Revenue ($m) by Segment, Historic, 2002-2009 139
Table 63: Microbiology Culture, Netherlands, Revenue ($m) by Segment, Forecast, 2009-2016 141
Table 64: Microbiology Analyzers, Netherlands, Revenue ($m) by Sub-Segment, Historic, 2002-2009 143
Table 65: Microbiology Analyzers, Netherlands, Revenue ($m) by Sub-Segment, Forecast, 2009-2016 145
Table 66: Microbiology Culture, Netherlands, Distribution Share by Revenue ($m), 2008-2009 146
Table 67: Microbiology Culture, Netherlands, Company Share by Revenue ($m), 2008-2009 148
Table 68: Clinical Chemistry Market Pipeline Products 163
Table 69: Immuno Chemistry Market Pipeline Products 165
Table 70: Haematology Market Pipeline Products 167
Table 71: Infectious Immunology Market Pipeline Products 168
Table 72: Microbiology Culture Market Pipeline Products 170
Table 73: Histology and Cytology Market Pipeline Products 171
Table 74: Genetic Testing Market Pipeline Products 172
Table 75: QIAGEN Enters Into Distribution Agreement With Celera 174
Table 76: Sequenom Enters Into Licensing Agreement With Optherion 175
Table 77: QIAGEN Enters Into Licensing Agreement With Johns Hopkins University 176
Table 78: DiaGenic Enters Into Distribution Agreement With Ferrer inCode 177
Table 79: OraSure Technologies Enters Into An Agreement With Roche Diagnostics 178
Table 80: Royal Philips Electronics Enters Into An Agreement With bioMerieux 179
Table 81: Technogenetics Signs Distribution Agreement With A. Menarini Diagnostics 180
Table 82: Inverness Medical Innovations Enters Into Distribution Agreement With Epocal 182
Table 83: Radient Pharmaceuticals Enters Into An Agreement With GenWay Biotech 183
Table 84: Amsterdam Molecular Therapeutics Enters Into An Agreement With Progenika Biopharma 184
Table 85: QIAGEN Enters Into An Agreement With Roche And Idaho Technology 185
Table 86: Leica Microsystems Signs An Agreement With A. Menarini Diagnostics 186
Table 87: USD to Local Currency, Netherlands, Average Actual Rate 2002-2009 205
List of Figures
1.2 List of Figures
Figure 1: In Vitro Diagnostics, Market Segmentation 16
Figure 2: In Vitro Diagnostics, Netherlands, Overall Revenue ($m), 2002-2016 17
Figure 3: In Vitro Diagnostics Market, Netherlands, Revenue Mix ($m), 2009 19
Figure 4: In Vitro Diagnostics Market, Netherlands, Category Contribution (%), 2009 20
Figure 5: In Vitro Diagnostics, Netherlands, Cross-Category Analysis, 2002-2016 21
Figure 6: In Vitro Diagnostics, Netherlands, Overall Revenue ($m), Historic, 2002-2009 22
Figure 7: In Vitro Diagnostics, Netherlands, Overall Revenue ($m), Forecast, 2009-2016 24
Figure 8: In Vitro Diagnostics, Netherlands, Company Share (%), 2009 26
Figure 9: Clinical Chemistry, Market Segmentation 28
Figure 10: Clinical Chemistry Market, Netherlands, Revenue Mix ($m), 2009 29
Figure 11: Clinical Chemistry, Netherlands, Category Contribution (%), 2009 30
Figure 12: Clinical Chemistry, Netherlands, Revenue ($m) by Segment, Historic, 2002-2009 31
Figure 13: Clinical Chemistry, Netherlands, Revenue ($m) by Segment, Forecast, 2009-2016 33
Figure 14: Clinical Chemistry Analyzers, Netherlands, Revenue ($m) by Sub-Segment, Historic, 2002-2009 35
Figure 15: Clinical Chemistry Analyzers, Netherlands, Revenue ($m) by Sub-Segment, Forecast, 2009-2016 37
Figure 16: Urine Analysis, Netherlands, Revenue ($m) by Sub-Segment, Historic, 2002-2009 39
Figure 17: Urine Analysis, Netherlands, Revenue ($m) by Sub-Segment, Forecast, 2009-2016 41
Figure 18: Clinical Chemistry, Netherlands, Company Share (%), 2009 44
Figure 19: Genetic Testing, Market Segmentation 46
Figure 20: Genetic Testing, Netherlands, Revenue Mix ($m), 2009 47
Figure 21: Genetic Testing, Netherlands, Category Contribution (%), 2009 48
Figure 22: Genetic Testing, Netherlands, Revenue ($m) by Segment, Historic, 2002-2009 49
Figure 23: Genetic Testing, Netherlands, Revenue ($m) by Segment, Forecast, 2009-2016 51
Figure 24: Genetic Testing, Netherlands, Company Share (%), 2009 54
Figure 25: Haematology, Market Segmentation 55
Figure 26: Heamatology, Netherlands, Revenue Mix ($m), 2009 56
Figure 27: Haematology, Netherlands, Category Contribution (%), 2009 57
Figure 28: Haematology, Netherlands, Revenue ($m) by Segment, Historic, 2002-2009 58
Figure 29: Haematology, Netherlands, Revenue ($m) by Segment, Forecast, 2009-2016 60
Figure 30: Haematology Reagents, Netherlands, Revenue ($m) by Sub-Segment, Historic, 2002-2009 62
Figure 31: Haematology Reagents, Netherlands, Revenue ($m) by Sub-Segment, Forecast, 2009-2016 64
Figure 32: Immunohaematology, Netherlands, Revenue ($m) by Sub-Segment, Historic, 2002-2009 66
Figure 33: Immunohaematology, Netherlands, Revenue ($m) by Sub-Segment, Forecast, 2009-2016 68
Figure 34: Haemostasis, Netherlands, Revenue ($m) by Sub-Segment, Historic, 2002-2009 70
Figure 35: Haemostasis, Netherlands, Revenue ($m) by Sub-Segment, Forecast, 2009-2016 72
Figure 36: Haematology Rapid Tests, Netherlands, Revenue ($m) by Sub-Segment, Historic, 2002-2009 74
Figure 37: Haematology Rapid Tests, Netherlands, Revenue ($m) by Sub-Segment, Forecast, 2009-2016 76
Figure 38: Haematology Cell Counters, Netherlands, Revenue ($m) by Sub-Segment, Historic, 2002-2009 78
Figure 39: Haematology Cell Counters, Netherlands, Revenue ($m) by Sub-Segment, Forecast, 2009-2016 80
Figure 40: Haematology, Netherlands, Company Share (%), 2009 83
Figure 41: Histology and Cytology, Market Segmentation 85
Figure 42: Histology and Cytology, Netherlands, Revenue Mix ($m), 2009 86
Figure 43: Histology and Cytology, Netherlands, Category Contribution (%), 2009 87
Figure 44: Histology And Cytology, Netherlands, Revenue ($m) by Segment, Historic, 2002-2009 88
Figure 45: Histology And Cytology, Netherlands, Revenue ($m) by Segment, Forecast, 2009-2016 90
Figure 46: Histology, Netherlands, Revenue ($m) by Sub-Segment, Historic, 2002-2009 92
Figure 47: Histology, Netherlands, Revenue ($m) by Sub-Segment, Forecast, 2009-2016 94
Figure 48: Histology And Cytology, Netherlands, Company Share (%), 2009 97
Figure 49: Immuno Chemistry, Market Segmentation 99
Figure 50: Immuno Chemistry, Netherlands, Revenue Mix ($m), 2009 100
Figure 51: Immuno Chemistry, Netherlands, Category Contribution (%), 2009 101
Figure 52: Immuno Chemistry, Netherlands, Revenue ($m) by Segment, Historic, 2002-2009 102
Figure 53: Immuno Chemistry, Netherlands, Revenue ($m) by Segment, Forecast, 2009-2016 104
Figure 54: Disease Specific Immunochemistry, Netherlands, Revenue ($m) by Sub-Segment, Historic, 2002-2009 106
Figure 55: Disease Specific Immunochemistry, Netherlands, Revenue ($m) by Sub-Segment, Forecast, 2009-2016 108
Figure 56: Drug Related Testing, Netherlands, Revenue ($m) by Sub-Segment, Historic, 2002-2009 110
Figure 57: Drug Related Testing, Netherlands, Revenue ($m) by Sub-Segment, Forecast, 2009-2016 112
Figure 58: Endocrinology Tests, Netherlands, Revenue ($m) by Sub-Segment, Historic, 2002-2009 114
Figure 59: Endocrinology Tests, Netherlands, Revenue ($m) by Sub-Segment, Forecast, 2009-2016 116
Figure 60: Immunochemistry Analyzers, Netherlands, Revenue ($m) by Sub-Segment, Historic, 2002-2009 118
Figure 61: Immunochemistry Analyzers, Netherlands, Revenue ($m) by Sub-Segment, Forecast, 2009-2016 120
Figure 62: Immuno Chemistry, Netherlands, Company Share (%), 2009 123
Figure 63: Infectious Immunology, Market Segmentation 125
Figure 64: Infectious Immunology, Netherlands, Revenue Mix ($m), 2009 126
Figure 65: Infectious Immunology, Netherlands, Category Contribution (%), 2009 127
Figure 66: Infectious Immunology, Netherlands, Revenue ($m) by Segment, Historic, 2002-2009 128
Figure 67: Infectious Immunology, Netherlands, Revenue ($m) by Segment, Forecast, 2009-2016 130
Figure 68: Infectious Immunology, Netherlands, Company Share (%), 2009 133
Figure 69: Microbiology Culture, Market Segmentation 135
Figure 70: Microbiology Culture, Netherlands, Revenue Mix ($m), 2009 136
Figure 71: Microbiology Culture, Netherlands, Category Contribution (%), 2009 137
Figure 72: Microbiology Culture, Netherlands, Revenue ($m) by Segment, Historic, 2002-2009 138
Figure 73: Microbiology Culture, Netherlands, Revenue ($m) by Segment, Forecast, 2009-2016 140
Figure 74: Microbiology Analyzers, Netherlands, Revenue ($m) by Sub-Segment, Historic, 2002-2009 142
Figure 75: Microbiology Analyzers, Netherlands, Revenue ($m) by Sub-Segment, Forecast, 2009-2016 144
Figure 76: Microbiology Culture, Netherlands, Company Share (%), 2009 147
Figure 77: F. Hoffmann-La Roche Ltd., Company Share (%),Netherlands In Vitro Diagnostics Market, 2009 149
Figure 78: Siemens Healthcare, Company Share (%),Netherlands In Vitro Diagnostics Market, 2009 151
Figure 79: Abbott Laboratories, Company Share (%),Netherlands In Vitro Diagnostics Market, 2009 152
Figure 80: bioMerieux S.A., Company Share (%),Netherlands In Vitro Diagnostics Market, 2009 153
Figure 81: Beckman Coulter, Inc., Company Share (%),Netherlands In Vitro Diagnostics Market, 2009 154
Figure 82: Ortho-Clinical Diagnostics Inc., Company Share (%),Netherlands In Vitro Diagnostics Market, 2009 155
Figure 83: GlobalData Methodology 202
To order this report:
In Vitro Diagnostic Industry: Brazil In Vitro Diagnostics Market Outlook to 2016
In Vitro Diagnostic Business News
Check our Company Profile, SWOT and Revenue Analysis!
Nicolas Bombourg |
|
Reportlinker |
|
Email: [email protected] |
|
US: (805)652-2626 |
|
Intl: +1 805-652-2626 |
|
SOURCE Reportlinker
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article